Liquid chromatography tandem mass spectrometry method for the quantification of rimonabant, a CB1 receptor antagonist, in human plasma

被引:11
作者
Nirogi, Ramakrishna [1 ]
Kandikere, Vishwottam [1 ]
Mudigonda, Koteshwara [1 ]
Ajjala, Devender [1 ]
机构
[1] Suven Life Sci Ltd, Biopharmaceut Res, Serene Chambers, Hyderabad 500034, Andhra Pradesh, India
关键词
rimonabant; liquid chromatography-tandem mass spectrometry; human plasma; pharmacokinetic study;
D O I
10.1002/bmc.955
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive high-performance liquid chromatography-tandem mass spectrometry method was developed and validated for the quantification of rimonabant in human plasma. Following liquid-liquid extraction, the analytes were separated using an isocratic mobile phase on a reverse-phase column and analyzed by MS/MS in the multiple reaction monitoring mode using the respective (M + H)(+) ions, m/z 463-363 for rimonabant and m/z 408-235 for the internal standard. The assay exhibited a linear dynamic range of 0.1-100 ng/mL for rimonabant in human plasma. The lower limit of quantification was 0.1 ng/mL with a relative standard deviation of less than 6%. With dilution integrity up to 10-fold, the upper limit of quantification was extendable up to 1000 ng/mL. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. A run time of 2.0 min for each sample made it possible to analyze more than 250 human plasma samples per day. The validated method was successfully used to analyze human plasma samples for application in pharmacokinetic studies. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:469 / 477
页数:9
相关论文
共 15 条
[1]   Rimonabant: The first therapeutically relevant cannabinoid antagonist [J].
Carai, MAM ;
Colombo, G ;
Gessa, GL .
LIFE SCIENCES, 2005, 77 (19) :2339-2350
[2]  
*EUR AG EV MED PRO, 2007, RIM SUMM PROD CHAR
[3]   Fused-core silica column high-performance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma [J].
Hsieh, Yunsheng ;
Duncan, Christine J. G. ;
Brisson, Jean-Marc .
ANALYTICAL CHEMISTRY, 2007, 79 (15) :5668-5673
[4]   Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening [J].
Hsieh, Yunsheng ;
Korfmacher, Walter A. .
CURRENT DRUG METABOLISM, 2006, 7 (05) :479-489
[5]  
Jemal M, 2000, BIOMED CHROMATOGR, V14, P422, DOI 10.1002/1099-0801(200010)14:6<422::AID-BMC25>3.0.CO
[6]  
2-I
[7]   The role of endocannabinoid system blockade in the treatment of the metabolic syndrome [J].
Kakafika, Anna I. ;
Mikhailidis, Dimitri P. ;
Karagiannis, Asterios ;
Athyros, Vasilios G. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (05) :642-652
[8]   Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS [J].
Matuszewski, BK ;
Constanzer, ML ;
Chavez-Eng, CM .
ANALYTICAL CHEMISTRY, 2003, 75 (13) :3019-3030
[9]   High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study [J].
Nirogi, RVS ;
Kandikere, VN ;
Shukla, M ;
Mudigonda, K ;
Maurya, S ;
Komarneni, P .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2006, 20 (12) :1864-1870
[10]   Drug treatments for obesity: orlistat, sibutramine, and rimonabant [J].
Padwal, Raj S. ;
Majumdar, Sumit R. .
LANCET, 2007, 369 (9555) :71-77